Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05392179 · ClinicalTrials.gov registry record · Phase 2
A Study in Subjects With Retinitis Pigmentosa
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05392179 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT05392179, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Interventions
- DRUG ADX-2191
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2023-06-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05392179
The ClinicalTrials.gov registry entry for NCT05392179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADX-2191 is the first listed.
NCT05392179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05392179 about?
NCT05392179 is a clinical study titled "A Study in Subjects With Retinitis Pigmentosa". An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
What is the current status of trial NCT05392179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-07-14. Estimated completion is 2023-06-23.
What interventions are being tested in trial NCT05392179?
The interventions under investigation include: ADX-2191 (DRUG).
Who is sponsoring clinical trial NCT05392179?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.